US2004096968A1PendingUtilityA1
Neural cultures
Priority: Nov 8, 1994Filed: Jun 25, 2003Published: May 20, 2004
Est. expiryNov 8, 2014(expired)· nominal 20-yr term from priority
Inventors:Bradley Stringer
C12N 2510/04C12N 5/0618
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a method of producing nerve cell-lines a homogeneous population of nerve cells having preselected biochemical/functional characteristics. In addition, the invention also concerns the provision of a homogeneous population of cells which can be selectively made to undergo apoptosis. Finally, the invention also concerns nerve cell-lines provided by the method of the invention.
Claims
exact text as granted — not AI-modified1 . A method for producing large populations of netural cells which method comprises undertaking the following steps in the following order;
a) enhancing the replication of a first undifferentiated neutral cell, or neural cell precursor cell, or precursor stem cell, b) exposing said replicated neural cells either to a region, or part thereof, of the nervous system, or an extract thereof including homologues and analogues thereof, from which said first neural cell came; and c) allowing differentiation of said cells to produce fully differentiated active neural cells.
2 . A method according to claim 1 wherein the enviornment from which the first nerve cell came is any region of the central nervous system.
3 . A method according to claim 2 wherein said environment is an environment at adjacent, or functionally related to the natural location in the central nervous system from which the first undifferentiated nerve cell is derived.
4 . A method according to claim 3 wherein said environment is a mitotic enviornment.
5 . A method according to any preceding claim wherein said nerve cells are exposed to a soluble extract from said environment.
6 . A method according to any preceding claim wherein said enviornment is from the same species as said first undifferentiated nerve cell.
7 . A method according to claims 1 to 5 wherein said environment is from a different species to that of said first undifferentiated nerve cell.
8 . A method according to any preceding claim wherein enhancing the replication is provided by use of a replication agent such as a growth factor.
9 . A method according to claims 1 to 7 wherein enhancing replication is provided by an immoraldising agent.
10 . A method according to claim 9 wherein said agent is an oncogene.
11 . A method according to claim 10 wherein said oncogene includes, or has associated therewith, a control means.
12 . A method according to claim 11 wherein said control means is responsive to culture or environmental conditions.
13 . A method according to claim 12 wherein said control means is responsive to temperature.
14 . A method according to claim 13 wherein said oncogene is SV40T.
15 . A method according to any preceding claim wherein said enviornment comprises an extract of cells from a region at, adjacent, or functionally related to the original region from which the first undifferentiated nerve cell is dervied.
16 . A method according to claims 1 to 14 wherein said environment comprises a soluble extract taken from a population of cells physiologically located at a region at, adjacent, or functionally related to the region from which the first undifferentiated nerve cell is derived.
17 . A method according to any preceding claim wherein said homogenous population of cells are exposed to at least one growth factor.
18 . A method according to any preceding claim which further includes transforming said first undifferentiated nerve cell with a safety feature gene which is either constitutive or can be selectively activated so as to enable, in either case, selective disabling or destruction of saie cell-line.
19 . Use of a nerve cell-line, which comprises a first undifferentiated nerve cell or nerve cell precursor cell that has been immortalised with an immortalising agent which includes or has associated therewith a control means whereby the immortalising agent can be selectively activited/deactivated, as a model for investigating apotosis whereby following culuring of said immortalised nerve cell so as to provide a homogeneous population of nerve cells prior to confluence said control means can be activated so as to remove the functionsl effect of the immortalising agent and so bring about cell apotosis.
20 . Cell-lines produced in accordance with the method of the claims 1 - 18 .
21 . A nerve cell-line according to claims 1 - 18 committed to a fully differentiated phenotype.
22 . A non-mitotic nerve cell-line according to claims 1 - 18 .
23 . A nerve cell-line that survives at low densities according to claims 1 - 18 .Join the waitlist — get patent alerts
Track US2004096968A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.